Physician profile

Michael Schwartz

Neurology (Psychiatry & Neurology) · Palos Heights, IL

NPI 1831109677

$1,486.78

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $261.98 2019
Ucb, INC. $186.32 2019
Biogen, INC. $132.80 2019-2020
Emd Serono, INC. $130.50 2019
Acorda Therapeutics, INC $129.76 2019
Teva Pharmaceuticals USA, INC. $116.73 2019-2021
Abbvie INC. $103.58 2019-2021
Genzyme Corporation $63.55 2019
Amgen INC. $54.43 2019
Lilly USA, LLC $53.61 2019-2020
Adamas Pharmaceuticals, INC. $37.84 2019
Livanova USA, INC. $31.27 2019
Pfizer INC. $23.57 2019
Mdd US Operations, LLC $23.56 2019
Akcea Therapeutics, INC. $20.25 2019
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Neurocrine Biosciences, INC. $20.00 2019
Alnylam Pharmaceuticals INC. $15.82 2019
Acadia Pharmaceuticals INC $14.82 2019
Alexion Pharmaceuticals, INC. $14.41 2019
Genentech USA, INC. $14.19 2019
Genentech, INC. $13.45 2019
Mallinckrodt Enterprises LLC $12.61 2019
Allergan, INC. $11.73 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Schwartz

$1,486.78

in general payments reported 2019-2025

Years
2019-2021
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/1098607/michael-schwartz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.